Kabra Drugs Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2016 - 2020
Net Income	-10.86	-7.36	-3.38	-1.85	-1.8	Upgrade
Depreciation & Amortization	0.07	-	-	0.1	0.31	Upgrade
Other Operating Activities	0.01	-	-	-	-	Upgrade
Change in Accounts Receivable	-	-	-	6.54	-	Upgrade
Change in Accounts Payable	-	17.28	-0.44	-5.29	-0.8	Upgrade
Change in Other Net Operating Assets	-36.29	-12	0.28	-0.84	-0.2	Upgrade
Operating Cash Flow	-47.07	-2.09	-3.54	-1.34	-2.49	Upgrade
Capital Expenditures	-0.51	-	-	-	-	Upgrade
Investing Cash Flow	-0.51	-	-	-	-	Upgrade
Short-Term Debt Issued	-	3.27	3.56	1.25	2.48	Upgrade
Total Debt Issued	-	3.27	3.56	1.25	2.48	Upgrade
Short-Term Debt Repaid	-12.71	-	-	-	-	Upgrade
Total Debt Repaid	-12.71	-	-	-	-	Upgrade
Net Debt Issued (Repaid)	-12.71	3.27	3.56	1.25	2.48	Upgrade
Issuance of Common Stock	246.57	25.5	-	-	-	Upgrade
Financing Cash Flow	233.86	28.77	3.56	1.25	2.48	Upgrade
Miscellaneous Cash Flow Adjustments	0	-	-	-	-	Upgrade
Net Cash Flow	186.28	26.68	0.02	-0.09	-0.01	Upgrade
Free Cash Flow	-47.58	-2.09	-3.54	-1.34	-2.49	Upgrade
Free Cash Flow Per Share	-4.34	-0.47	-0.81	-0.30	-0.57	Upgrade
Levered Free Cash Flow	-47.51	0.68	-2.32	-0.64	-1.81	Upgrade
Unlevered Free Cash Flow	-47.51	0.68	-2.32	-0.64	-1.81	Upgrade
Change in Net Working Capital	36.29	-5.28	0.17	-0.42	1	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.